id,agency_id,docket_id,title,document_type,subtype,posted_date,posted_year,posted_month,comment_start_date,comment_end_date,last_modified,fr_doc_num,open_for_comment,withdrawn,object_id
FDA-2015-P-1153-0006,FDA,FDA-2015-P-1153,"Response Letter from FDA CDER to Lachman Consultant Services, Inc.",Other,Letter(s),2015-11-25T05:00:00Z,2015,11,2015-11-25T05:00:00Z,,2015-11-25T19:29:16Z,,0,0,0900006481d743a6
FDA-2015-P-1153-0005,FDA,FDA-2015-P-1153,"Determination That TYLENOL WITH CODEINE (Acetaminophen With
Codeine Phosphate) Oral Tablets, 325 Milligrams/7.5 Milligrams, 325
Milligrams/15 Milligrams, 325 Milligrams/30 Milligrams, and 325
Milligrams/60 Milligrams, Were Not Withdrawn From Sale for Reasons of
Safety or Effectiveness",Notice,Determinations,2015-11-25T05:00:00Z,2015,11,2015-11-25T05:00:00Z,,2015-11-25T16:14:27Z,2015-30051,0,0,0900006481d72983
FDA-2015-P-1153-0004,FDA,FDA-2015-P-1153,"Interim Response Letter from FDA CDER to Lachman Consultant Services, Inc.",Other,Letter(s),2015-10-07T04:00:00Z,2015,10,2015-10-07T04:00:00Z,,2015-11-18T19:48:57Z,,0,0,0900006481cb6007
FDA-2015-P-1153-0003,FDA,FDA-2015-P-1153,"Attachment 1 Orange Book Approved Drug Products with Therapeutic Equivalence Evaluations Citizen Petition from Lachman Consultant Services, Inc.",Supporting & Related Material,Background Material,2015-04-10T04:00:00Z,2015,4,,,2015-04-10T12:11:17Z,,0,0,0900006481a94cc2
FDA-2015-P-1153-0002,FDA,FDA-2015-P-1153,"Acknowledgement Letter from FDA DDM to Lachman Consultant Services, Inc.",Other,Acknowledgement Letter/Receipt,2015-04-10T04:00:00Z,2015,4,2015-04-10T04:00:00Z,,2015-04-10T12:09:48Z,,0,0,0900006481a94cc0
FDA-2015-P-1153-0001,FDA,FDA-2015-P-1153,"Citizen Petition from Lachman Consultant Services, Inc.",Other,Citizen Petition,2015-04-10T04:00:00Z,2015,4,2015-04-10T04:00:00Z,,2015-11-25T19:26:02Z,,0,0,0900006481a94cbe